Statins inhibit insulin-like growth factor action in first trimester placenta by altering insulin-like growth factor 1 receptor glycosylation
Open Access
- 9 October 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Molecular Human Reproduction
- Vol. 21 (1) , 105-114
Abstract
The rapid rise in obesity, metabolic syndrome and type 2 diabetes is one of the major healthcare problems of the Western world. Affected individuals are often treated with statins (3-hydroxy-3-methylglutaryl co-enzyme A [HMG CoA] reductase inhibitors) to reduce circulating cholesterol levels and the risk of developing cardiovascular disease; given the evolving demographic profile of these conditions, such drugs are increasingly prescribed to women of reproductive age. We have previously shown that exposure of placental tissue to statins inhibits the action of insulin-like growth factors (IGF)-I and -II which are key regulators of trophoblast proliferation and placental development. N-linked glycans in the IGF receptor, IGF1R, influence its presentation at the cell surface. This study aimed to determine whether statins, which are known to affect N-glycosylation, modulate IGF1R function in placenta. Treatment of first trimester villous tissue explants with statins (pravastatin or cerivastatin) or inhibitors of N-glycosylation (tunicamycin, deoxymannojirimycin or castanospermine) altered receptor distribution in trophoblast and attenuated proliferation induced by IGF-I or IGF-II (Ki67; P < 0.05, n = 5). Decreased binding of Phaseolus vulgaris lectin and phytohaemagglutinin to IGF1R immunoprecipitated from treated explants demonstrated reduced levels of complex N-linked glycans. Co-incubation of tissue explants with statins and farnesyl pyrophosphate (which increases the supply of dolichol intermediates), prevented statin-mediated disruption of IGF1R localization and reversed the negative effect on IGF-mediated trophoblast proliferation. These data suggest that statins attenuate IGF actions in the placenta by inhibiting N-linked glycosylation and subsequent expression of mature IGF1R at the placental cell surface.Keywords
This publication has 66 references indexed in Scilit:
- Can statins prevent pregnancy complications?Journal of Reproductive Immunology, 2014
- N-Linked Glycosylation Supports Cross-Talk between Receptor Tyrosine Kinases and Androgen ReceptorPLOS ONE, 2013
- Statins and PregnancyDrugs, 2012
- Heterodimerization of Glycosylated Insulin-Like Growth Factor-1 Receptors and Insulin Receptors in Cancer Cells Sensitive to Anti-IGF1R AntibodyPLOS ONE, 2012
- Apposite Insulin-like Growth Factor (IGF) Receptor Glycosylation Is Critical to the Maintenance of Vascular Smooth Muscle Phenotype in the Presence of Factors Promoting Osteogenic Differentiation and MineralizationJournal of Biological Chemistry, 2011
- Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse modelProceedings of the National Academy of Sciences, 2010
- Statins are detrimental to human placental development and function; use of statins during early pregnancy is inadvisableJournal of Cellular and Molecular Medicine, 2008
- Simvastatin inhibits the proliferation of human prostate cancer PC-3 cells via down-regulation of the insulin-like growth factor 1 receptorBiochemical and Biophysical Research Communications, 2008
- A dot blot technique for the analysis of interactions of lectins with glycosaminoglycansJournal of Molecular Histology, 1992
- Dolichol: function, metabolism, and accumulation in human tissuesBiochemistry and Cell Biology, 1992